Last updated on November 2017

RTOG 1010: A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma


Brief description of study

RTOG 1010: A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma

Detailed Study Description

For more information please visit: http://clinicaltrials.gov/ct2/show/NCT01196390?term=RTOG+1010&rank=1

Clinical Study Identifier: TX4446

Contact Investigators or Research Sites near you

Start Over

Patricia Green

Memorial Health University Medical Center
Savannah, GA USA

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.